Temporal trends in the prescription of low-dose antithrombotic and anti-inflammatory therapies in Germany (2022-2024).

Kunz, M; Daudí, AE; Kieble, M; Laufs, U; Götzinger, F; Boeddinghaus, J; Leibundgut, G; Meier, CR; Müller, C; Schulz, M; Mahfoud, F

Temporal trends in the prescription of low-dose antithrombotic and anti-inflammatory therapies in Germany (2022-2024).

Kunz, M Daudí, AE Kieble, M Laufs, U Götzinger, F Boeddinghaus, J Leibundgut, G Meier, CR Müller, C Schulz, M

Mahfoud, F

Permalink

Publisher:: SPRINGER HEIDELBERG
Publication Type:: Journal Article
Citation:: Clin Res Cardiol, 2025
Issue Date:: 2025-10-07

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (1.01 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Kunz, M
dc.contributor.author	Daudí, AE
dc.contributor.author	Kieble, M
dc.contributor.author	Laufs, U
dc.contributor.author	Götzinger, F
dc.contributor.author	Boeddinghaus, J
dc.contributor.author	Leibundgut, G
dc.contributor.author	Meier, CR
dc.contributor.author	Müller, C
dc.contributor.author	Schulz, M https://orcid.org/0000-0002-5876-7322
dc.contributor.author	Mahfoud, F
dc.date.accessioned	2026-02-26T01:16:44Z
dc.date.available	2025-09-13
dc.date.available	2026-02-26T01:16:44Z
dc.date.issued	2025-10-07
dc.identifier.citation	Clin Res Cardiol, 2025
dc.identifier.issn	1861-0684
dc.identifier.issn	1861-0692
dc.identifier.uri	http://hdl.handle.net/10453/193713
dc.description.abstract	AIMS: This study aimed to investigate the prescription rates of low-dose antithrombotic and anti-inflammatory therapies in Germany from 2022 to 2024. METHODS: We analyzed national outpatient claims data from the German Institute for Drug Use Evaluation. Claims data for patients receiving the following medications were included: aspirin 100 mg, clopidogrel 75 mg, prasugrel 5 mg and 10 mg, ticagrelor 60 mg and 90 mg, rivaroxaban 2.5 mg, and colchicine 0.5 mg. Drug utilization was quantified using defined daily doses per 1000 Statutory Health-insured persons per day (DID, 10 DID = approximately 1% of the population receive the drug daily). RESULTS: In 2024, aspirin had the highest dispensing volume (47.4 DID), followed by clopidogrel (10.6 DID). All other substances were infrequently prescribed: prasugrel 5 mg (0.065 DID) and 10 mg (1.388 DID), ticagrelor 60 mg (0.103 DID) and 90 mg (0.978 DID), rivaroxaban 2.5 mg (1.535 DID), and colchicine (0.457 DID). Rivaroxaban 2.5 mg was the only drug showing a notable increase in utilization over time (+ 42% from 2022 to 2024). Cardiologists accounted for a small proportion of prescriptions (mean DID share 3.3%, 1.8% of all dispensed DDD). Aspirin use increased consistently with age, while rivaroxaban 2.5 mg peaked in the 70-74 age group. In contrast, ticagrelor 60 mg was more frequently prescribed in middle-aged patients. CONCLUSION: Despite the high prevalence of coronary artery disease (CAD), the use of long-term antithrombotic and anti-inflammatory therapies for secondary prevention in patients with CAD remains low in Germany, especially among older patients.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	SPRINGER HEIDELBERG
dc.relation.ispartof	Clin Res Cardiol
dc.relation.isbasedon	10.1007/s00392-025-02761-x
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1102 Cardiorespiratory Medicine and Haematology
dc.subject.classification	Cardiovascular System & Hematology
dc.subject.classification	3201 Cardiovascular medicine and haematology
dc.title	Temporal trends in the prescription of low-dose antithrombotic and anti-inflammatory therapies in Germany (2022-2024).
dc.type	Journal Article
utslib.location.activity	Germany
utslib.for	1102 Cardiorespiratory Medicine and Haematology
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Health
utslib.copyright.status	open_access	*
dc.rights.license	This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/
dc.date.updated	2026-02-26T01:16:31Z
pubs.publication-status	Published online

Abstract:

AIMS: This study aimed to investigate the prescription rates of low-dose antithrombotic and anti-inflammatory therapies in Germany from 2022 to 2024. METHODS: We analyzed national outpatient claims data from the German Institute for Drug Use Evaluation. Claims data for patients receiving the following medications were included: aspirin 100 mg, clopidogrel 75 mg, prasugrel 5 mg and 10 mg, ticagrelor 60 mg and 90 mg, rivaroxaban 2.5 mg, and colchicine 0.5 mg. Drug utilization was quantified using defined daily doses per 1000 Statutory Health-insured persons per day (DID, 10 DID = approximately 1% of the population receive the drug daily). RESULTS: In 2024, aspirin had the highest dispensing volume (47.4 DID), followed by clopidogrel (10.6 DID). All other substances were infrequently prescribed: prasugrel 5 mg (0.065 DID) and 10 mg (1.388 DID), ticagrelor 60 mg (0.103 DID) and 90 mg (0.978 DID), rivaroxaban 2.5 mg (1.535 DID), and colchicine (0.457 DID). Rivaroxaban 2.5 mg was the only drug showing a notable increase in utilization over time (+ 42% from 2022 to 2024). Cardiologists accounted for a small proportion of prescriptions (mean DID share 3.3%, 1.8% of all dispensed DDD). Aspirin use increased consistently with age, while rivaroxaban 2.5 mg peaked in the 70-74 age group. In contrast, ticagrelor 60 mg was more frequently prescribed in middle-aged patients. CONCLUSION: Despite the high prevalence of coronary artery disease (CAD), the use of long-term antithrombotic and anti-inflammatory therapies for secondary prevention in patients with CAD remains low in Germany, especially among older patients.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/193713